Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
Q3 2022 vs. Q2 2022
How the institutions holding Evotec SE changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 21 | 22 | +1 |
| Shares | 4.78M | 4.94M | +165.5K (+3.5%) |
| Value | $57.3M | $43.5M | −$13.8M (−24.1%) |
New holders (3)
Institutions that held Evotec SE at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 13,699 | $120.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,152 | $10.0K | 0.00% |
| Wipfli Financial Advisors LLC, | 158 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Evotec SE at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Optiver Holding B.V. | 165,234 | $1.98M |
| Wells Fargo & Company | 5,500 | $66.0K |